Neuroendocrine differentiation of prostate cancer

来源 :亚洲男性学杂志(英文版) | 被引量 : 0次 | 上传用户:yuhuipin1
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Prostate cancer is a major health risk for men in Western countries as it is the most common malignancy and the second leading cause of cancer-related deaths.In some countries where prostate cancer is traditionally uncommon such as China,the incidence of prostate cancer has also shown a dramatic increase in recent years.rnLow grade,organ-confined prostate cancers are curable by surgery or radiation therapy.For patients with recurrent or metastatic prostate cancer,hormonal therapy,by inhibiting androgen production and/or blocking androgen receptor (AR) function,is the treatment of choice.Unfortunately,hormonal therapy is not curative and the cancer nearly always recurs after an initial period of response and inevitably progresses to the castra-tion resistant stage.
其他文献
期刊
Dear Editor,rnWe have recently developed a novel surgical approach for themanagement of bilateral testicular hypotrophy,allowing both thepreservation of gonadic function and some penile lengthening:aimof this letter is to describe our surgical technique,r
期刊
@@
In a pivotal phase 3 randomized controlled trial,Hussain et al.tested the hypothesis that,with respect to survival,intermittent androgen deprivation therapy (ADT) is non-inferior to continuous in men with newly diagnosed metastatic prostate cancer.While t
期刊
Urotensin?II (U?II) is a cyclic peptide that acts through a G protein?coupled receptor (urotensin?II receptor [UTR]) mainly involved in cardiovascular function in humans. The urotensinergic system is also implicated in the urogenital tract. Indeed, U?II r